Table 3.
Clinical features, angiographic characteristics, and treatment of young patients after a coronary event with or without FH
| Variable | Total | FH statusa | |||
|---|---|---|---|---|---|
| Probable/Definite (> 5 points) |
Possible (3–5 points) |
None (< 3 points) |
P | ||
| Diagnosis | |||||
| STEMI, n(%) | 468 (54.1) | 16 (43.2) | 126 (48.6) | 326 (57.3) | 0.027 |
| NONSTEMI, n(%) | 75 (8.7) | 0 (0.0) | 29 (11.2) | 46 (8.1) | 0.054 |
| UAP, n(%) | 314 (36.3) | 21 (56.8) | 101 (39.0) | 192 (33.7) | 0.010 |
| SAP, n(%) | 8 (0.9) | 0 (0.0) | 3 (1.2) | 5 (0.9) | 0.774 |
| Coronary angiography | |||||
| None, n(%) | 100 (11.6) | 1 (2.7) | 33 (12.7) | 66 (11.6) | 0.216 |
| Single vessel, n(%) | 448 (51.8) | 8 (21.6) | 131 (50.6) | 309 (54.3) | 0.001 |
| Double vessel, n(%) | 195 (22.5) | 13 (35.1) | 57 (22.3) | 125 (21.9) | 0.173 |
| Triple vessel, n(%) | 110 (12.7) | 13 (35.1) | 34 (13.1) | 63 (11.1) | 0.000 |
| Left main, n(%) | 61 (7.1) | 3 (8.1) | 13 (5.0) | 45 (7.9) | 0.312 |
| CTO, n(%) | 270 (31.2) | 17 (45.9) | 83 (32.2) | 170 (29.9) | 0.115 |
| Multivessel lesion, n (%) | 317 (36.6) | 28 (75.7) | 95 (36.7) | 194 (34.1) | 0.000 |
| Gensini | 32 (10–64) | 50 (14–82) | 32 (10–64) | 32 (9–56) | 0.008 |
| Operation | |||||
| PCI, n(%) | 539 (62.3) | 20 (54.1) | 176 (68.0) | 343 (60.3) | 0.061 |
| CABG, n(%) | 90 (10.4) | 12 (32.4) | 17 (6.6) | 61 (10.7) | 0.000 |
| PTCA, n(%) | 20 (2.3) | 0 (0.0) | 6 (2.3) | 14 (2.5) | 0.628 |
| Medication at discharge | |||||
| Aspirin, n(%) | 819 (94.7) | 36 (97.3) | 251 (96.9) | 532 (93.5) | 0.098 |
| β-blocker, n(%) | 701 (81.0) | 26 (70.3) | 216 (83.4) | 459 (80.7) | 0.151 |
| ACEI/ARB, n(%) | 472 (54.6) | 13 (35.1) | 146 (56.4) | 313 (55.0) | 0.049 |
| Statins, n(%) | 719 (83.1) | 28 (75.7) | 226 (87.3) | 465 (81.7) | 0.067 |
| High-dose statins, n(%) | 67 (7.7) | 2 (5.4) | 21 (8.1) | 44 (7.7) | 0.847 |
| Ezetimibe, n(%) | 40 (4.6) | 9 (24.3) | 15 (5.8) | 16 (2.8) | 0.000 |
FH familial hypercholesterolemia, pCAD premature coronary artery disease, STEMI ST-segment elevation myocardial infarction, NONSTEMI Non-ST-segment elevation myocardial infarction, UAP Unstable angina pectoris, SAP Stable angina pectoris, CTO chronic total occlusion, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, PTCA percutaneous transluminal coronary angioplast, ACEI/ARB angiotensin converting enzyme inhibitors/angiotensin receptor blocker
aBased on Dutch Lipid Clinic Network criteria